Yousif Capital Management LLC Has $17.25 Million Stake in Pfizer Inc. (NYSE:PFE)

Yousif Capital Management LLC lowered its stake in Pfizer Inc. (NYSE:PFE) by 2.2% in the fourth quarter, Holdings Channel reports. The fund owned 650,247 shares of the biopharmaceutical company’s stock after selling 14,784 shares during the quarter. Yousif Capital Management LLC’s holdings in Pfizer were worth $17,251,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in PFE. Czech National Bank lifted its holdings in shares of Pfizer by 6.9% in the third quarter. Czech National Bank now owns 1,154,366 shares of the biopharmaceutical company’s stock worth $33,407,000 after acquiring an additional 74,737 shares during the last quarter. GAMMA Investing LLC raised its holdings in Pfizer by 48.9% in the 3rd quarter. GAMMA Investing LLC now owns 39,904 shares of the biopharmaceutical company’s stock valued at $1,155,000 after buying an additional 13,097 shares during the last quarter. Diversified Trust Co raised its holdings in Pfizer by 33.8% in the 3rd quarter. Diversified Trust Co now owns 113,505 shares of the biopharmaceutical company’s stock valued at $3,285,000 after buying an additional 28,658 shares during the last quarter. Ignite Planners LLC raised its holdings in Pfizer by 1.5% in the 3rd quarter. Ignite Planners LLC now owns 34,144 shares of the biopharmaceutical company’s stock valued at $988,000 after buying an additional 518 shares during the last quarter. Finally, Chapin Davis Inc. raised its holdings in Pfizer by 2.8% in the 3rd quarter. Chapin Davis Inc. now owns 59,981 shares of the biopharmaceutical company’s stock valued at $1,736,000 after buying an additional 1,627 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE PFE opened at $25.88 on Wednesday. The company has a fifty day simple moving average of $26.27 and a 200 day simple moving average of $27.82. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The company has a market cap of $146.64 billion, a P/E ratio of 34.97, a PEG ratio of 0.66 and a beta of 0.64.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter last year, the firm posted $0.10 EPS. Pfizer’s revenue was up 24.7% compared to the same quarter last year. Sell-side analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a $0.43 dividend. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a yield of 6.65%. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is presently 232.44%.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on PFE shares. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Wolfe Research began coverage on shares of Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 price target for the company. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Wednesday, October 23rd. Truist Financial lowered their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Finally, UBS Group lowered their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.